Regeneron: Analysts Regain Confidence in Innovative Treatments

Solid Catalysts Transform Market Outlook

Sentiment around Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is experiencing a significant positive shift, driven by a combination of advances in existing treatments and promising pipeline developments. This renewed enthusiasm is reflected in recent analyst adjustments, which indicate a more accurate valuation of the biotech company’s growth opportunities.

Expanded Pipeline and Strategic Partnerships

In the therapeutic landscape, Regeneron continues to expand its portfolio through meaningful collaborations. In December 2025, the company established a global partnership with Tessera Therapeutics Inc. for the development and commercialization of TSRA-196, Tessera’s leading in vivo Gene Writing experimental therapy. This drug aims to treat alpha-1 antitrypsin deficiency (AATD), a hereditary condition affecting the lungs, liver, or both, representing a significant opportunity in the gene therapy segment.

Meanwhile, in October 2025, Regeneron released updated results for DB-OTO, its experimental gene therapy designed to address severe genetic hearing loss caused by mutations in the otoferlin gene (OTOF).

BofA Securities’ Promotion and Underlying Fundamentals

On Wednesday, Bank of America (BofA) Securities upgraded its rating on Regeneron Pharmaceuticals, with analyst Tazeen Ahmad changing the assessment from Underperform to Buy, while raising the target price from $627 a $860. This decision reflects an overall reassessment of the company’s growth prospects.

Eylea HD: The New Growth Driver

Ahmad’s renewed confidence particularly focuses on Eylea HD, where recent label expansions and the anticipated approval of a pre-filled syringe version expected by mid-2026 open new market opportunities. Industry feedback indicates that larger treatment centers—handling most anti-VEGF treatments—are increasingly favoring Eylea HD over competing products like Vabysmo.

BofA’s previous cautious stance on Eylea SD has been reflected in downward consensus forecasts, but Ahmad now anticipates a substantially different trajectory for Eylea HD, with estimated revenues for the U.S. Eylea franchise of $4.35 billion in 2026, surpassing current consensus estimates.

Additional Development Vectors

BofA also highlights encouraging prospects from Dupixent, developed in partnership with Sanofi SA (NASDAQ: SNY), along with promising pipeline opportunities for 2026. Notably, the completion of Phase 3 for fianlimab (LAG-3) in melanoma is expected in the first half of the year.

Future Catalysts

Additional potentially positive elements include expected developments at a major competitor’s conference in January, as well as a likely favorable resolution of Regeneron’s Most Favored Nation (MFN) negotiations with the federal administration. A positive outcome could remove uncertainty from the stock, including a possible exemption from the demonstration projects under MFN CMMI.

Market Performance

REGN stock movement: At the time of the report on Wednesday, Regeneron shares gained 4.60%, reaching $812.27 and hitting a new 52-week high according to Benzinga Pro data.

Stock snapshot:

• Regeneron Pharmaceuticals Inc (REGN): $812.91 (+4.60%)
• Sanofi SA (SNY): $47.92 (-0.93%)